Sign in
RT

Rani Therapeutics Holdings, Inc. (RANI)·Q1 2024 Earnings Summary

Executive Summary

  • Rani reported Q1 2024 net loss of $14.8M and diluted EPS of $(0.29), improving from $(16.8)M and $(0.33) in Q1 2023 on lower R&D and G&A from cost actions .
  • Cash, cash equivalents and marketable securities were $39.6M as of March 31, 2024 (down from $48.5M at Dec 31, 2023), highlighting a funding watch item into upcoming catalysts .
  • Clinical progress remained the focus: positive Phase 1 topline for oral anti-IL‑12/23 mAb RT‑111; Phase 2 RT‑102 (osteoporosis) expected in 2024; RaniPill HC targeted to be Phase 1–ready in H2 2024 .
  • Guidance was operational (program milestones) rather than financial; there was no explicit revenue/margin guidance. S&P Global consensus estimates were unavailable via our system for Q1 2024, so we do not present beat/miss vs Street this quarter (see Estimates Context) .

What Went Well and What Went Wrong

What Went Well

  • Positive RT‑111 Phase 1 topline: high bioavailability, well-tolerated, no SAEs; potential differentiated dosing profile in autoimmune disorders. CEO: “We believe that RT‑111 could have a favorable product profile… in the competitive landscape for autoimmune disorders.”
  • Operating discipline: R&D fell to $7.6M (from $9.7M YoY) primarily on workforce reductions and lower third‑party costs; G&A fell to $6.4M (from $6.8M) with lower compensation and other costs, narrowing net loss YoY .
  • Clear near‑term milestones: Phase 2 RT‑102 in 2024 and RaniPill HC readiness for potential Phase 1 in H2 2024—key development catalysts to watch .

What Went Wrong

  • Liquidity trended lower: cash, cash equivalents and marketable securities declined to $39.6M from $48.5M at year‑end, elevating financing risk if timelines extend .
  • Near‑term obligations rose: current portion of long‑term debt increased to $8.6M from $4.9M at Dec 31, 2023, tightening near‑term balance sheet flexibility .
  • No commercial revenue in the quarter; continued net losses with stock‑based comp of $3.9M included, keeping cash burn in focus for investors .

Financial Results

P&L: Prior Year, Prior Quarter, Current Quarter

MetricQ1 2023Q4 2023Q1 2024
Revenue ($USD Millions)— — —
R&D Expense ($USD Millions)$9.71 $7.61 $7.59
G&A Expense ($USD Millions)$6.80 $5.83 $6.45
Total Operating Expenses ($USD Millions)$16.52 $13.44 $14.03
Net Loss ($USD Millions)$(16.83) $(14.06) $(14.78)
Diluted EPS ($)$(0.33) $(0.27) $(0.29)

Notes: Company reported no revenue lines in the quarterlies cited; margins not meaningful given no revenue .

Liquidity and Balance Sheet (point-in-time)

MetricDec 31, 2023Mar 31, 2024
Cash, Cash Equivalents & Marketable Securities ($USD Millions)$48.5 $39.6
Cash & Cash Equivalents ($USD Millions)$5.86 $6.88
Marketable Securities ($USD Millions)$42.68 $32.70
Total Assets ($USD Millions)$57.92 $53.51
Current Portion of LT Debt ($USD Millions)$4.90 $8.59
LT Debt (less current) ($USD Millions)$24.48 $20.85
Total Liabilities ($USD Millions)$32.47 $38.98
Total Stockholders’ Equity ($USD Millions)$25.44 $14.54

KPIs and Other Metrics

KPIQ1 2023Q1 2024
Stock-based Compensation (included in net loss) ($USD Millions)$4.4 $3.9
Weighted Avg Class A Shares (Basic & Diluted) (Millions)25.24 26.03

Guidance Changes

Metric/ItemPeriodPrevious Guidance (as of Q4 2023 release)Current Guidance (Q1 2024)Change
RT‑102 Phase 2 initiation2024Initiation expected in 2024 Initiation expected in 2024 Maintained
RaniPill HC Phase 1 readinessH2 2024Ready for potential Phase 1 in H2 2024 Ready for potential Phase 1 in H2 2024 Maintained

No quantitative revenue/margin guidance provided in either release .

Earnings Call Themes & Trends

Note: A Q1 2024 call transcript was not available in our document set; themes reflect Q3 2023 (press) and Q4 2023 (call) for prior context, and Q1 2024 press for the current period .

TopicPrevious Mentions (Q3 2023, Q4 2023)Current Period (Q1 2024)Trend
R&D execution / platform validationStrategic prioritization; advancing RaniPill HC; initiated RT‑111 Phase 1; multiple preclinical HC successes RT‑111 Phase 1 topline positive; continued platform messaging Positive continuity
Partnerships / BDCelltrion supply agreements and ROFN on RT‑111; exploring partnerships for HC No new deals in Q1 PR; later in Q2: ProGen collaboration (context, after Q1) Pipeline optionality building (post‑Q1)
Obesity / incretin programsHigh priority area; platform fit for next‑gen incretins; dosing/tolerability rationale (Q4 call) Not central in Q1 PR; operational focus on RT‑102/HC Steady priority (brief in Q1 PR)
Cost discipline / runwayCost containment, runway into 2025; need for additional capital (Q4 call) Lower R&D/G&A YoY; liquidity down to $39.6M Mixed: opex control, liquidity decline
Regulatory/clinical milestonesRT‑111 Phase 1 positive; plan RT‑102 Phase 2 design (Q4 call) RT‑102 Phase 2 2024; HC H2 2024 readiness reiterated On track vs prior commentary

Management Commentary

  • CEO positioning: “We believe that RT‑111 could have a favorable product profile… [and] the RaniPill platform has the potential to combine the efficacy… of a monoclonal antibody with the convenience… of a pill” .
  • Program milestones reiterated: RT‑102 Phase 2 to initiate in 2024; RaniPill HC targeted to be ready for potential Phase 1 in H2 2024 .
  • From the prior call (Q4 2023) on platform validation and capital planning: management underscored positive RT‑111 data, advancing HC automation, and the need to raise additional capital beyond the current runway (into 2025) .

Notable quotes

  • “We are pleased with the progress we have made in the first quarter having announced positive topline results from our Phase 1 study for RT‑111.” – CEO Talat Imran .
  • “We look forward to providing updates throughout the year as we make progress on our programs and continue to evaluate opportunities for Rani to deliver upon its mission to end painful injections…” – CEO .

Q&A Highlights

A Q1 2024 earnings call transcript was not available in our corpus. For continuity of investor themes, highlights from the Q4 2023 call:

  • Partnering and cost share for RT‑111 with Celltrion under discussion; if partnered, partner would likely bear costs; otherwise Rani would seek capital for a Phase 2 repeat‑dose study .
  • Obesity strategy: aim for dosing schedules and tolerability improvements leveraging RaniPill; portfolio approach across next‑gen incretins and mechanisms; strong partner interest .
  • Manufacturing/automation: building a pilot automated line targeting thousands of pills/day for later‑stage needs; current capacity sufficient for Phase 1/2 .

Estimates Context

  • Wall Street consensus (S&P Global) for Q1 2024 was unavailable via our system at the time of retrieval; therefore, we do not present a beat/miss vs consensus this quarter. Values retrieved from S&P Global were unavailable due to system limits.
  • Given the lack of revenue and continued operating expenses, Street models typically focus on opex trajectory and cash runway; the YoY declines in R&D and G&A, plus the cash balance change, are the key inputs that may drive estimate revisions on opex and runway assumptions .

Key Takeaways for Investors

  • Clinical validation de‑risking: Positive RT‑111 Phase 1 supports the oral biologics thesis and underpins optionality in autoimmune programs and broader platform partnering discussions .
  • Cost discipline evident but cash trending lower: YoY opex down, net loss narrowed, yet total liquidity fell to $39.6M—funding overhang remains a central factor into 2024 catalysts .
  • 2024 catalysts are operational: RT‑102 Phase 2 start and RaniPill HC Phase 1 readiness are the near‑term potential stock movers (trial initiation, study designs, early data flow) .
  • Balance sheet watch: current portion of debt rose, shifting obligations nearer term; monitor financing pathways (equity/BD) against milestone cadence .
  • Narrative trajectory: management continues to emphasize platform breadth and dosing/tolerability advantages versus existing oral approaches—key for differentiated positioning in autoimmune and obesity markets over time .

Appendix: Additional Context

  • Prior Quarter (Q4 2023) summary metrics for context: R&D $7.6M, G&A $5.8M, net loss $(14.1)M, EPS $(0.27) .
  • Q3 2023 context: strategic program prioritization and HC progress set the stage for 2024 focus on RT‑102, RT‑111, and HC .

Sources: Rani Q1 2024 8‑K and press release (May 6, 2024) ; Q4 2023 8‑K and call (Mar 20, 2024) -; Q3 2023 8‑K (Nov 8, 2023) -.